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National Institutes of Health, Bethesda, Maryland 20892-3017Respiratory syncytial virus (RSV) is a pneumovirus in
the family Paramyxoviridae. It is a pleomorphic envel-
oped virus about 150 nm in diameter, transmitted by
large particle aerosol and fomites, resulting in yearly
epidemics of respiratory disease. RSV infects nearly 70%
of infants in their first year of life and everyone by age
three (Glezen and Denny, 1973). Reinfection is common.
About 50% of children infected in the first year of life are
reinfected in the second year of life, and everyone is
reinfected every two to three years throughout life.
RSV disease syndromes. There are several distinct
disease syndromes associated with RSV infection. While
most infants have mild disease, about 5% of those less
than one year of age require hospitalization. The peak
hospitalization rate is in infants between 2 and 3 months
of age. Those with bronchopulmonary dysplasia and
congenital heart disease are at greatest risk, but most
hospitalized children have no apparent underlying con-
dition. The virus infects both ciliated and nonciliated
cells in small (75–300 m in diameter) airways, resulting
in a bronchiolitis characterized clinically by wheezing.
Bronchoalveolar lavage (BAL) reveals a predominance of
polymorphonuclear leukocytes in respiratory secretions.
However, tissue sections reveal a predominance of lym-
phocytes in the peribronchiolar and perivascular spaces,
and small airways containing fibrin, mucus, and a mix-
ture of sloughed epithelial cells and inflammatory cells.
In addition, RSV infects the alveolar epithelium, particu-
larly Type 1 alveolar pneumocytes. This component of
RSV pathology is underappreciated despite signs of
lower airway disease such as hypoxia that are com-
monly found even in asymptomatic patients.
Most normal children and adults experience mild up-
per respiratory disease during reinfection with RSV, al-
1 To whom correspondence and reprint requests should be addressed1though underlying asthma and chronic bronchitis can be
exacerbated during infection. However, in the institution-
alized elderly, disease can be severe and in some stud-
ies has been associated with as much excess mortality
as influenza (Falsey et al., 1995). The pathology is less
distinctive in this setting and is often complicated by
chronic lung disease, heart failure, and bacterial super-
infection. Therefore, it is difficult to ascribe disease
pathogenesis to a direct manifestation of virus-mediated
cytopathology and virus-induced inflammation, or to ex-
acerbation of underlying conditions.
RSV infection is associated with high mortality in pa-
tients with immunodeficiency. This is particularly true in
the setting of severe combined immunodeficiency dis-
ease (Fishaut et al., 1980), and in patients following
allogenic bone marrow (Hertz et al., 1989) or lung trans-
plantation (Krinzman et al., 1998). Solid organ transplant
recipients, patients with malignancies, or persons with
other selected immune deficiencies have milder disease.
The disease syndrome is a giant cell pneumonia with
widespread syncytium formation in epithelial cells, pre-
sumably a direct result of virus-induced cytopathology.
Finally, RSV has a legacy of vaccine-enhanced dis-
ease. Four studies using a Formalin-inactivated, alum-
precipitated whole virus vaccine (FI-RSV) were per-
formed in children in the mid-1960s. Vaccine-induced
immune responses did not protect against subsequent
natural infection, and disease severity was increased.
Among vaccinated children in the youngest age group,
80% required hospitalization and some died (Kim et al.,
1969). This tragedy has motivated extensive study of
disease pathogenesis in animal models over the last 25
years and led to the current paradigms that guide vac-
cine development and approaches to therapy.
Serological studies in the children with RSV vaccine-
enhanced illness showed poor neutralizing activity and
fusion-inhibiting activity in the antibody response to vac-
cine (Murphy et al., 1986, 1988), perhaps explaining theReceived February 22, 20
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does not explain why illness was enhanced. They were
also found to have high lymphoproliferative responses to
RSV antigens (Kim et al., 1976) and a relatively high
frequency of eosinophilia (Chin et al., 1969). Tissue sec-
tions from the children who died demonstrate a typical
distribution of inflammation around the small airways,
but the composition of the infiltrate is different from
primary infection with an abundance of eosinophils and
neutrophils in addition to mononuclear cells (Fig. 1).
There was no evidence of extensive, virus-induced cyto-
pathology. These observations suggested a virus-spe-
cific cell-mediated immune process was responsible for
the enhanced illness.
The findings in animal models that relate to the syn-
drome of the RSV vaccine-enhanced illness will be re-
viewed. In particular, how the current understanding of
vaccine-enhanced illness pathogenesis can inform our
understanding of disease associated with primary RSV
infection will be addressed. The central focus will be on
how prior antigen exposure can induce aberrant adap-
tive immune responses, and how those responses can
cause disease. The pathogenesis of RSV in the institu-
tionalized elderly or immunocompromised patients will
not be discussed in detail.
Murine model of RSV. A murine model of RSV has been
used to study the pathogenesis of vaccine-enhanced
illness. Most work has been done in BALB/c mice that
are relatively permissive to RSV replication compared to
other strains. However, the murine model has some
limitations that should be recognized in the interpretation
of results. The infection is initiated in anesthetized mice
by intranasal inoculation of a large volume of high titer
virus. The inoculum is aspirated directly into lung. Virus
replication occurs primarily in the alveolar parenchyma
in Type 1 pneumocytes (Figs. 2A and 2B). There is evi-
dence of bronchiolar cytopathology in some strains, and
immune infiltration occurs around arterioles and bron-
chioles, as well as in the alveolar interstitium. Illness is
mediated predominantly by the T cell response to infec-
tion (Graham et al., 1991b). Therefore, the murine model
provides a good system to ask how the composition of
the inflammatory infiltrate is regulated in response to
RSV infection. It is not a good model for studying disease
caused by virus-induced cytopathology in airway epithe-
lium. It is also not a good system for studying the kinetics
of primary RSV infection or the role of early events me-
diated by innate immunity, because the inoculum is so
high and is delivered directly into the lung. These types
of questions should be addressed in systems in which
the virus is specific for the host, and a low inoculum can
initiate infection in the upper respiratory tract that sub-
sequently spreads to the lower airway. Examples include
pneumonia virus of mice (PVM) or Sendai infection in
mice, BRSV in calves, or RSV in humans. With these
caveats in mind, using the murine model to study the
composition and regulation of adaptive immune re-
sponses induced by RSV has distinct advantages be-
cause of the wealth of immunological reagents and ge-
netically defined strains available.
The Th2 hypothesis of RSV pathogenesis. In mice
immunized with FI-RSV and then challenged with RSV,
one sees an inflammatory infiltrate composed of mono-
cytes, lymphocytes, and numerous eosinophils demon-
strated by their large cytoplasmic granules (Fig. 2C). This
is reminiscent of the pathology seen in infants with
FI-RSV vaccine-enhanced disease. The pathology is de-
pendent on CD4 T cells. Lung extracts from mice chal-
lenged with RSV after FI-RSV immunization show a dom-
inant IL-4 mRNA pattern, whereas the dominant re-
sponse in mice immunized with live RSV given
intramuscularly or intranasally is IFN- (Graham et al.,
1993). These findings suggested that an aberrant CD4
Th2 response may be the basis for the RSV vaccine-
enhanced illness syndrome. The mechanism by which
this occurs is still controversial as discussed below.
When the RSV vaccine-enhanced illness was associ-
ated with CD4 Th2 responses, it promoted an interest in
the role of Type 2 cytokines in the pathogenesis of
primary RSV infection. Primary RSV infection is associ-
ated with wheezing, and severe disease requiring hos-
pitalization is associated with a higher incidence of sub-
sequent childhood asthma (Sigurs et al., 1995). Some
groups have shown RSV-specific IgE can be found in
respiratory secretions of children with severe disease
(Welliver et al., 1981), and others have shown an increase
of eosinophilic cationic protein (Garofalo et al., 1992),
findings consistent with Type 2 cytokine activity. How-
ever, others have shown children with severe disease
have a dominant IFN- response without direct evidence
of the classical Type 2 cytokines IL-4 or IL-5 (Branden-
burg et al., 2000).
How is the RSV-specific Th2 response induced in FI-
RSV vaccine-enhanced illness? The RSV G glycoprotein
is part of the envelope spike on the surface of the virus
and is the putative attachment protein. G has a number
of interesting structural features. It is a type II integral
membrane protein anchored at the amino terminus.
About 50% of the protein produced is secreted from the
infected cell because of an alternative initiation codon in
the transmembrane domain (Roberts et al., 1994). About
60% of the molecular weight is O-glycosylation, and there
is a high serine and threonine content and a very high
proline content making it more homologous to mucins
than any known viral glycoprotein. The glycosylation is
concentrated on either end of the molecule, and in the
central portion there is a cysteine noose with a known
heparan sulfate binding domain (Feldman et al., 1999)
and a CX3CR binding motif (Tripp et al., 2001).
RSV G has equally interesting antigenic properties.
Despite careful analysis, there has never been a G-
specific CD8 T cell response reported. The reason for
this is not known. It is probably not due to a defect in
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FIG. 1. Haematoxylin and eosin-stained lung section from the autopsy of a child who died in the one of the original FI-RSV trials complicated by
vaccine-enhanced illness. The box in (A) framing a segment of the bronchiole is shown at higher magnification in (B). One of the many eosinophils
is marked by a white arrow.
FIG. 2. RSV infection of BALB/c mice is restricted primarily to the alveolar epithelial cells. (A) In situ hybridization of RSV RNA in a lung section taken
on day 4 after RSV challenge. (B) Transmission electron micrograph of Type 1 alveolar pneumocytes with budding filamentous RSV on day 4 of
infection. The bar represents 200 nm. (C) Transmission electron micrograph of lung section from a mouse immunized with FI-RSV and subsequently
challenged with RSV. Eosinophils are demonstrated by white arrows and by the presence of large cytoplasmic granules.
FIG. 3. Impact of CD8 CTL killing mechanisms on RSV pathogenesis. (A) illustrates the process of clearing RSV infection under normal
circumstances. CD8 cytotoxic T lymphocytes (CTL) recognize RSV-infected epithelial cells through T cell receptor interactions with RSV-derived
peptides presented in MHC class I molecules. The majority of infected cells are eliminated via secretion of perforin and granzymes by CTL. However,
FasL expression (lightning bolt) by activated CTL also participates in mediating apoptosis of RSV-infected cells. In addition, Type 1 cytokines, such
as IFN- and TNF-, are secreted by CTL in modest amounts. These combined processes are hypothesized to selectively induce apoptosis (Red X)
in RSV-infected cells with very little injury of uninfected cells. (B) represents the immune response hypothesized to occur in the setting of Type 2
cytokines, particularly IL-4. Increased IL-4 leads to upregulation of FasL on activated CTL. Since most cells express a basal level of Fas, the
augmented expression of FasL on CTL may result in bystander killing of uninfected cells along with killing of RSV-infected cells. In addition, the less
efficient CTL produce exaggerated levels of IFN- and TNF-. The altered CTL activity in this setting is hypothesized to increase bystander killing
and to cause more severe lung pathology and enhanced illness.
3MINIREVIEW
processing MHC class I-restricted epitopes contained
within G, since the H-2Kd-restricted CTL epitope from M2
inserted into G and expressed in vaccinia can induce a
CTL response (Srikiatkachorn and Braciale, 1997). The
lack of MHC class I-restricted response to G suggests
that the memory T cell response to G is heavily biased
toward MHC class II-restricted CD4 T cells. Openshaw
et al. (1992) first showed that mice immunized with re-
combinant vaccinia expressing RSV G develop an eosin-
ophil response in lung and BAL following RSV challenge.
Recombinant vaccinia expressing WT G, but none of the
other RSV proteins, results in a significant percentage of
eosinophils in BAL. They subsequently showed this re-
sponse was dependent on the genetic background of the
mouse (Hussell et al., 1998). Several groups then
showed that G contains a dominant MHC class II-re-
stricted epitope (aa 184–198) that induces both Th1 and
Th2 CD4 T cells (Tebbey et al., 1998; Sparer et al., 1998;
Srikiatkhachorn et al., 1999). This epitope is in the region
of the heparan sulfate binding domain and just down-
stream of the cysteine noose structure. Varga et al. then
showed the CD4 T cells responding to this epitope
predominantly utilize V14 in their T cell receptors (Varga
et al., 2001).
These unique properties of G begged the question,
were G-specific immune responses responsible for the
RSV vaccine-enhanced illness? This has obvious impli-
cations for vaccine development since if true, G deter-
minants could simply be removed from vaccine products.
However, most of the antigenic variation present in RSV
isolates occurs in the carboxyl-terminus of G, suggesting
that G is an important target for the immune response
and is under selective pressure to change. Therefore,
including G in vaccine formulations would be advanta-
geous.
There are several arguments that G antigenic deter-
minants were not the essential factor in the FI-RSV vac-
cine-enhanced illness. They include the following:
1. G is expressed on wild-type virus, which typically
leads to a Th1-type response in primary infection.
2. The G-induced response in mice is dependent on
the genetic background, is epitope dependent, and is
restricted to selected T cell receptors utilizing V14. In
contrast, FI-RSV immunization seemed to lead to en-
hanced disease in virtually all individuals, suggesting
that it was not dependent on the genetic background or
restricted to a single epitope or T cell receptor.
3. Pathology, illness, and immune responses similar
to those elicited by FI-RSV can be elicited by purified RSV
F glycoprotein, especially when formulated in alum (Gra-
ham et al., 1993; Hancock et al., 1996).
However, there are other properties of G that could
affect the virus-specific immune response. G is produced
early in the infected cell and secreted (Hendricks et al.,
1987). Therefore it is one of the first RSV proteins avail-
able in the extracellular milieu for processing through the
endocytic pathway and presentation to CD4 T cells.
This may allow certain G-specific CD4 T cell responses
to occur prior to the modulating influences of IFN-
produced by CD8 T cells and NK cells. In addition, the
secreted G can bind to heparan sulfate moieties (Feld-
man et al., 1999), fractalkine receptor (Tripp et al., 2001),
or lectin-like proteins (Barr et al., 2000), perhaps trigger-
ing signaling events that influence subsequent immune
responses.
We have asked whether the property of G secretion is
important for inducing the Type 2 cytokine profile, eosin-
ophilia, and pathology associated with the vaccine-en-
hanced illness. Recombinant vaccinia viruses encoding
WT G (vvGwt), membrane-anchored G (vvGr), or secreted
G (vvGs) were produced by Sharon Roberts in the labo-
ratory of Dr. Gail Wertz (Roberts et al., 1994). The vaccinia
constructs were inoculated by intradermal injection at
the base of the tail, and RSV challenge was performed 6
weeks later. We first asked how immunization affected
eosinophil responses in BAL following subsequent RSV
infection. Mock immunization or vacF does not lead to
postchallenge eosinophil responses. In contrast FI-RSV
and vvGs induce a robust eosinophilia. Membrane-an-
chored G induces eosinophilia, but to a much lesser
extent, and the vvGwt (a mixture of both membrane
anchored and secreted G) induces an intermediate re-
sponse (Johnson et al., 1998). We next asked whether the
eosinophil response required IL-4, using both antibody
inhibition with the anti-IL-4 monoclonal antibody, 11B.11,
and IL-4 knockout mice (Johnson et al., 1999). Earlier
studies had shown that FI-RSV-induced eosinophilia fol-
lowing subsequent challenge was IL-4 dependent (Tang
et al., 1994). These studies showed that the eosinophilia
induced by RSV infection following immunization with the
secreted G does not require IL-4. This led us to ask
whether the G-induced response was associated with
IL-13, which is induced at high levels after G immuniza-
tion. We used IL-4 knockout mice in combination with an
IL-13 receptor antagonist. As before we showed that the
G-induced eosinophilia occurred in IL-4 KO mice,
whereas the FI-RSV induced eosinophilia does not occur
in IL-4 KO mice. Similarly, IL-13 receptor antagonist alone
did not attenuate G-induced eosinophilia, but did elimi-
nate FI-RSV-induced eosinophilia. Interestingly, if IL-13
receptor antagonist is given to IL-4 KO mice, G is not
able to induce eosinophils. This indicates that IL-4 and
IL-13 are able to compensate for each other to allow
G-induced eosinophilia, but both cytokines are needed
for FI-RSV to induce the response (T. R. Johnson et al.,
submitted).
These findings support the concept that G-specific
epitopes were not necessarily responsible for eliciting
the vaccine-enhanced illness and suggest that the pat-
tern of immunizing parenterally with an antigen pro-
cessed and presented through the endocytic pathway in
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MHC class II molecules followed by airway infection with
RSV has the potential to elicit a Type 2 immune re-
sponse. This sequence of parenteral immunization fol-
lowed by airway challenge is known to elicit airway
hypersensitivity and eosinophil responses even when
using a model antigen such as ovalbumin (Willis-Karp,
1999). As mentioned above, purified F formulated in alum
followed by RSV infection also results in airway eosino-
philia (Graham et al., 1993). Likewise, priming mice with
recombinant vaccinia expressing a secreted F glycopro-
tein, as opposed to the wild-type membrane-anchored F,
also induces IL-4 production following RSV challenge
(Bembridge et al., 1999). Therefore, any immunization
strategy in RSV-naı¨ve infants based on products with
obligate processing through the endocytic pathway and
presentation strictly to CD4 T lymphocytes may have
the capacity to elicit the vaccine-enhanced illness.
RSV has other properties that may promote Type 2
cytokine production. RSV shares a legacy of vaccine-
enhanced illness with measles. In both cases vaccina-
tion was with whole inactivated virus that elicited poor
functional antibody responses. There is evidence in both
cases that the enhanced illness was caused by an ab-
errant T cell response. Both viruses are in the family
Paramyxoviridae and share several properties. In partic-
ular, both viruses have innate mechanisms for inhibiting
the effects of IFN-/ (Naniche et al., 2000; Schlender et
al., 2000). The NS1 and NS2 proteins of bovine RSV have
been shown to antagonize the antiviral effects of IFN-/
(Schlender et al., 2000). Durbin et al. have also shown
that the lack of IFN-/-mediated signaling during RSV
infection promotes eosinophilia and Type 2 cytokine pro-
duction (Durbin et al., 2002). It seems likely that this may
be an important determinant in why RSV is associated
with vaccine-enhanced illness and other disease syn-
dromes associated with Type 2 cytokine production.
However, more work is needed on how IFN-/ influ-
ences the differentiation of T cells, and how interference
with these pathways contributes to the pathogenesis of
RSV and other virus infections.
Do Type 2 cytokines play a role in the pathogenesis of
severe primary RSV infection? RSV infections in young
infants requiring hospitalization are associated with ev-
idence of eosinophil cationic protein in airway secre-
tions. However, it is not clear whether disease in this
setting is a manifestation of Type 2 cytokine production
or not. Type 2 cytokines are not found in respiratory
secretions of these infants. In contrast, large amounts of
IFN- are found (Brandenburg et al., 2000). It is possible
that Type 2 cytokines are acting locally, but evaluation of
cytokine production from peripheral blood mononuclear
cells (PBMCs) of RSV-infected children (Anderson et al.,
1994) and studies in animal models do not bear that out.
Primary infection with RSV in mice does not induce
significant levels of Type 2 cytokine production unless
there is some prior stimulus such as allergic airway
sensitization with ovalbumin (Peebles et al., 2001a) or
priming with pertussis toxin (Samore and Siber, 1996;
Fischer et al., 1999). In a murine model of PVM eosino-
philia is seen following primary infection, but it is not a
consequence of IL-5 and the adaptive immune response.
Rather, it occurs early in infection and is mediated largely
by MIP-1 and other components of the innate immune
response (Domachowske et al., 2000). This model of a
pneumovirus matched to its natural host may better re-
flect the early events following infection than the model
using human RSV in the mouse. It is possible that in
children with underlying atopy or other factors predis-
posing to a Type 2 cytokine environment the response to
primary RSV infection may be more likely to involve Th2
CD4 T cells. This has been demonstrated in mice
(Peebles et al., 2001a), but more work is needed in clinical
studies to define whether this happens in humans.
How do Type 2 cytokines influence disease severity
during virus infection? While there are many observa-
tions of pathogens that have more severe disease in the
setting of excess Type 2 cytokine production, the mech-
anisms of disease enhancement are poorly defined. In
the airway, increased mucus production could contribute
to airway obstruction, or eosinophil recruitment and de-
granulation could lead to direct tissue damage. Th2
CD4 T cells are not inherently more pathogenic, and in
the setting of autoimmunity they are less destructive than
Th1 CD4 T cells. In many cases it appears that the
mechanisms for clearance of the pathogen are less
effective, resulting in direct tissue damage from the
pathogen itself. However, in the murine model of RSV
and other viruses, the enhanced illness is not related to
direct pathogen-induced cytopathology, but is dependent
on the immune response. Therefore, we asked how IL-4
influenced the mechanisms of RSV clearance and how
these immunological effectors influenced disease patho-
genesis. Two early observations led us to focus on CD8
T cells as a key mediator of this process. First, inhibiting
IL-4 during FI-RSV immunization improved CD8 T cell
response following subsequent challenge and led to
reduced illness (Tang and Graham, 1994). Second, CD8
T cell-mediated RSV clearance is diminished and pathol-
ogy is enhanced in IL-4 overexpressing mice (Fischer et
al., 1997). These findings suggested that IL-4 may be
altering functional properties of CD8 T cells, causing
them to have less efficient cytolytic function and to pro-
duce more pathology.
We therefore constructed recombinant vaccinia vi-
ruses to express the RSV M2 protein that contains a
defined H-2Kd-restricted T cell epitope with or without
coexpression of IL-4. Using these vectors, we showed
that IL-4 coexpression reduced the total cytolytic capac-
ity of the M2-specific CD8 T cells (Aung et al., 1999).
This raised the question of which cytolytic mechanisms
were affected. Naı¨ve CD8 T cells recognize processed
peptides in the context of MHC class I molecules and
5MINIREVIEW
become activated after costimulation through interaction
between B7 and CD28. This leads to upregulated expres-
sion of selected molecules. When a virus-infected cell is
detected by TCR interaction with the relevant epitope,
perforin is released and allows the entry of granzymes
and serine proteases into the target cell. This is a cal-
cium-dependent process. In addition, FasL expression is
upregulated and interaction with Fas can lead to cal-
cium-independent signaling. Both pathways can lead to
apoptosis and cell death. In general perforin-mediated
lysis is more targeted and FasL-mediated lysis is less
specific and more likely to result in antigen-independent
bystander killing.
We found that coexpression of IL-4 with RSV M2 in
recombinant vaccinia increases FasL expression on the
M2-specific CD8 T cells resulting in diminished per-
forin-mediated cytolytic activity and enhanced FasL-me-
diated target cell killing (Aung and Graham, 2000). Ex-
periments in perforin KO mice confirmed that perforin
was not necessary for RSV clearance, but when other
cytolytic mechanisms are used, clearance and disease
expression are delayed, and illness is more prolonged.
In addition, excess production of IFN- and TNF- in
lung temporally correlated with the illness (Aung et al.,
2001). In contrast, when FasL-defective (gld) mice are
infected with RSV, viral clearance occurs with normal
kinetics with minimal illness and normal amounts of
IFN- and TNF- (J. A. Rutigliano, unpublished observa-
tions). These observations suggest a new working hy-
pothesis for the mechanism of severe illness in RSV. We
propose that the critical pathogenic event that causes
illness in primary RSV infection is an aberrant CD8 T
cell response. Specifically, inefficient cytolytic mecha-
nisms will lead to delayed and prolonged virus clear-
ance, and bystander injury may be the basis of enhanced
pathology in settings where too much reliance is placed
on FasL-mediated mechanisms of lysis and cytotoxic
cytokines (Fig. 3). An important corollary of this hypoth-
esis is that immunization approaches that induce sub-
sets of CD8 CTL responses with efficient, targeted
killing mechanisms should result in more favorable out-
comes. These concepts will be the subject of future
studies in murine models and clinical trials.
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